Rubric Capital Management LP

Institutional investor · Portfolio as of Q2 2024

Q2 2024 biggest moves
  • JAZZJAZZ

    Jazz Pharmaceuticals

    New

    1.7% of portfolio

  • ALITALIT

    Alight

    New

    1.6% of portfolio

  • LBTYALBTYA

    Liberty Global, both classes

    Added 58%

    now 4.2% of portfolio

  • ATMUATMU

    Atmus Filtration Technologies

    Sold out

    was 1.1% of portfolio

52 changes in all

Top Holdings68 positions

Checking export access…
Activity:
TEVA
TEVA
ADR

Teva Pharmaceutical Industries Limited

17.3M$280.5M7.4%$7.88+106.16%
6 qtrssince 2023-Q1
Decreased
0
ROIV

Roivant Sciences Ltd.

23M$243.1M6.4%$10.71-1.29%
7 qtrssince 2022-Q4
Increased
68
VTRS

Viatris Inc.

20.1M$214.1M5.6%$9.08+6.71%
5 qtrssince 2023-Q2
Increased
65
GLNG

Golar LNG Limited

6.5M$204.9M5.4%$12.01+146.96%
13 qtrssince 2021-Q2
Increased
59
BGC

BGC Group, Inc.

19M$157.7M4.1%$5.16+58.02%
4 qtrssince 2023-Q3
Unchanged
0
FLR

Fluor Corporation

3.2M$140M3.7%$34.56+26.02%
11 qtrssince 2021-Q4
Increased
67
COOP
COOPDelisted

MR COOPER GROUP INC

1.5M$123.4M3.2%——
19 qtrssince 2019-Q4
Unchanged
0
QDEL

QuidelOrtho Corporation

3.6M$121.1M3.2%$49.78-33.27%
4 qtrssince 2023-Q3
Increased
77
VST

Vistra Corp.

1.3M$114.1M3.0%$69.90+21.31%
2 qtrssince 2024-Q1
Increased
56
LBTYA

Liberty Global Ltd.

5.5M$96.3M2.5%$9.03-0.59%
3 qtrssince 2023-Q4
Increased
69
HRTX

Heron Therapeutics, Inc.

26.7M$93.5M2.5%$1.84+90.36%
8 qtrssince 2022-Q3
Unchanged
0
ARQT

Arcutis Biotherapeutics, Inc.

9.8M$91.3M2.4%$10.26-9.32%
9 qtrssince 2022-Q2
Increased
65
RNW

ReNew Energy Global plc

13.5M$84.3M2.2%$6.08+2.60%
10 qtrssince 2022-Q1
Increased
59
COLL

Collegium Pharmaceutical, Inc.

2.3M$75.1M2.0%$21.49+49.84%
18 qtrssince 2020-Q1
Increased
58
CAR

Avis Budget Group, Inc.

690,273$72.1M1.9%$110.11-5.08%
2 qtrssince 2024-Q1
Increased
75
EXTR

Extreme Networks, Inc.

5.3M$70.7M1.9%$12.20+10.28%
2 qtrssince 2024-Q1
Increased
65
CSTM

Constellium SE

3.7M$69M1.8%$17.87+5.50%
6 qtrssince 2023-Q1
Increased
47
AMRX

Amneal Pharmaceuticals, Inc.

10.7M$68.1M1.8%$5.13+23.70%
5 qtrssince 2023-Q2
Increased
52
MATV

Mativ Holdings, Inc.

4M$67.8M1.8%$17.22-10.39%
8 qtrssince 2022-Q3
Unchanged
0
JAZZ

Jazz Pharmaceuticals plc

616,617$65.8M1.7%$106.73+4.38%
1 qtr
New
68
$3.8B
AUM
68
Positions
Q2 2024
Filing
HI rating · 2.5/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2023-Q1$3,856,770,89568.1455533844%
2023-Q2$2,338,598,459-39.3638221541%
2023-Q3$2,665,984,08913.999223712%
2023-Q4$4,819,423,75980.7746632429%
2024-Q1$3,383,423,498-29.7960987207%
2024-Q2$3,813,863,16412.7220156228%
Activity profile
$ moved · Q2'24
New19%Increased52%Decreased12%Exited16%
Composition
Equity vs derivatives
Equity99%Puts0%Calls1%
Holding period
Avg 1.7 years
<1Q9%1-4Q26%1-2Y25%2Y+40%

Rubric Capital Management LP manages $3.8B across 68 positions as of Q2 2024. Top holdings: TEVA (7.4%), ROIV (6.4%), VTRS (5.6%). Fund DNA: High Conviction Activist. HoldingsIntel Score: 2.5/5.0.

Top holdings by portfolio weight

Total AUM$4B
TEVA7.35%
ROIV6.37%
VTRS5.61%
GLNG5.37%
BGC4.13%
FLR3.67%
COOP3.23%
QDEL3.18%
VST2.99%
LBTYA2.53%
Other2.45%

Portfolio allocation by GICS sector

Sectors11
Healthcare49.24%
Technology9.15%
Industrials7.83%
Utilities6.11%
Communication Services6.02%
Unknown5.78%
Energy5.41%
Financial Services4.16%
Basic Materials3.96%
Consumer Defensive1.66%
Other0.68%

Behavioral investing profile

Checking access…
High Conviction Activist- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(2.5 / 5.0)
Holdings P&L34
Conviction64
Concentration69
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
6Q
GEOGEOThe Geo Group Inc
Q2 2025 → Q3 2026+4.5M shares+$138.3M
5Q
BGCBGCBGC Group, Inc.
Q3 2025 → Q3 2026+9.3M shares+$129.2M
5Q
VTRSVTRSViatris Inc.
Q3 2025 → Q3 2026+24M shares+$530.8M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used